DeepVerge PLC: Microtox® BT Evaluation of SARS-CoV-2 from breath test with Clinical Samples
Press release content from Globe Newswire. The AP news staff was not involved in its creation. DeepVerge PLC: Microtox® BT Evaluation of SARS-CoV-2 from breath test with Clinical Samples Deepverge PLCMarch 17, 2021 GMT YORK, United Kingdom, March 17, 2021 (GLOBE NEWSWIRE) -- DeepVerge (LSE:DVRG.L), the environmental and life science AI company, announces initial data for ongoing Phase III clinical studies on the detection of SARS-CoV-2 on breath samples and identification of confirmed COVID19 positive patients . Since Q3 2020, DeepVerge scientists have been working under laboratory cond...
Source: apnews.com